echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Long-term outcomes of second-line nivolumab in advanced esophageal cancer

    Clin Cancer Res: Long-term outcomes of second-line nivolumab in advanced esophageal cancer

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Esophageal cancer is one of the most aggressive gastrointestinal cancers and the seventh leading cause of cancer-related deaths worldwide, with approximately 6,041,000 new cases of esophageal cancer worldwide in 2020
    .
    Data on long-term prognostic information in patients with advanced esophageal squamous cell carcinoma (ESCC) treated with immune checkpoint inhibitors are limited


    .


    6041000

    ATTRACTION-3 is a randomized, multicenter, open-label Phase 3 trial in which nivolumab vs chemotherapy (paclitaxel or docetaxel) in previously treated ESCC patients is reported.
    3-year follow-up data
    .

    This article reports 3-year follow-up data from this trial of nivolumab versus chemotherapy (paclitaxel or docetaxel) in previously treated ESCC patients
    .

    Patients 20 years of age and older with unresectable advanced or recurrent ESCC were randomized (1:1) to receive nivolumab or chemotherapy (paclitaxel or docetaxel) until disease progression or intolerable toxicity


    .


    overall survival


    Overall survival in both groups


    Overall survival in both groups Overall survival in
    both groups

    A total of 419 patients were enrolled, of which 210 received nivolumab and 209 received chemotherapy
    .
    The shortest follow-up was 36.
    0 months, and the overall survival in the nivolumab group was longer than in the chemotherapy group (median overall survival: 10.
    9 months vs 8.
    5 months, HR 0.


    79, p=0.
    0264), and the 3-year overall survival rates were 15.
    3 % and 8.
    7%


    Overall survival was longer in the nivolumab group than in the chemotherapy group .



    In conclusion, our findings suggest that nivolumab has a long-term overall survival advantage over chemotherapy as second-line therapy for previously treated advanced esophageal cancer
    .
    Compared with chemotherapy, patients in the nivolumab group had longer overall survival with or without best response, and nivolumab was well tolerated


    .


    Nivolumab has a long-term overall survival advantage over chemotherapy as second-line therapy for previously treated advanced esophageal cancer


    Original source:

    Original source:

    Morihito Okada, et al.
    Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).


    Clin Cancer Res OF1–OF10.
    https://doi.


    Morihito Okada, et al.
    Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).
    Clin Cancer Res OF1–OF10.
    https://doi.
    org/ 10.
    1158/1078-0432.
    CCR-21-0985.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.